Messenger RNA has redefined what rapid looks like in drug development. Yet the very flexibility that makes mRNA attractive also makes it unforgiving—minute variations in purity, structure, or LNP encapsulation can eliminate potency or introduce safety risks. It’s never too soon to…
The remarkable success of messenger RNA-based vaccines during the COVID-19 pandemic has sparked widespread interest and enthusiasm around mRNA technology. But vaccines are just the beginning. Researchers and biotech innovators worldwide are rapidly uncovering the broader potential of mRNA to…
Given the strides medical researchers and therapeutic developers were making, the possibility of commercializing mRNA therapeutics began looking bright about ten to fifteen years ago. However, one of the most pressing issues restricting researchers’ efforts was the lack of a…
How an mRNA-encoded antibody platform could accelerate therapies to clinic Therapeutic antibody production is traditionally complex and costly, which drives up treatment prices. However, encoding antibodies with mRNA offers a potential solution to many of these challenges, making the process…
mRNA for Antibody Manufacturing In collaboration, Charles River Lab and Vernal Biosciences released this scientific poster. Since its release, new advancements have been made and new data is available to share. Join the webinar on December 12 to dive into…
In this talk, we dive into the critical quality attributes (CQAs) of mRNA and lipid nanoparticles (LNPs) that directly impact drug efficacy and safety. You’ll gain insights into essential and cutting-edge analytical techniques and nanopore sequencing, mass spectrometry, and laser-induced…
New Leadership Reflects Commitment to Advancing mRNA Technologies and Operational Excellence, Helping Drug Developers Deliver Innovative Therapies Faster. COLCHESTER, Vt., October 31, 2024 /BUSINESS WIRE/ — Vernal Biosciences Inc., a leader in mRNA and lipid nanoparticle (LNP) development, manufacturing, and…
Nature Nanotechnology: Tissue-Specific mRNA Therapeutic Delivery Researchers have developed a combinatorial design of siloxane-incorporated LNPs to enhance tissue-specific mRNA therapeutic delivery. This article explains how this approach improves intracellular processing and stability of mRNA, showing promise for targeted treatments and…
In this video series exploring biotech innovation, Christian Cobaugh, founder and CEO of Vernal, discusses the critical role of analytical services in the success of mRNA and lipid nanoparticles (LNPs) therapeutics. Interviewed by Kristyn Cook, Executive Director of Marketing, he…
COLCHESTER, Vt., October 9, 2024 — Vernal Biosciences, a leader in mRNA and lipid nanoparticle (LNP) manufacturing, announces that its analytical and quality control (QC) services for plasmid DNA, mRNA, and LNPs are now commercially available as part of its…
In the fast-paced world of early-stage mRNA product and process development, it’s not just about ideas and innovation; it’s about how quickly and accurately you can measure your outcomes. Since those precious outcomes depend on the confidence you have in…
Speaking of Mol Bio Podcast In the latest episode (Season 2, Episode 8) of the Speaking of Mol Bio Podcast, hosts Steve Lewis and Dr. Christian Cobaugh, CEO of Vernal Biosciences, delve into the fascinating world of mRNA technology. The…